481630-99-3

Basic information

• Product Name: 5-(3-CHLOROPHENYL)-1H-INDOLE
• Synonyms: 5-(3-CHLOROPHENYL)-1H-INDOLE;AKOS BAR-1288
• CAS NO: 481630-99-3
• Molecular Formula: C₁₄H₁₀ClN
• Molecular Weight: 227.69
• Mol File: 481630-99-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(3-CHLOROPHENYL)-1H-INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-CHLOROPHENYL)-1H-INDOLE(481630-99-3)
• EPA Substance Registry System: 5-(3-CHLOROPHENYL)-1H-INDOLE(481630-99-3)

Safety Data

• Hazardous Substances Data: 481630-99-3(Hazardous Substances Data)

Upstream product

• 10075-50-0 5-bromo-1H-indole 
• 63503-60-6 3-chlorophenylboronic acid 

Downstream Products

• 708257-85-6 [5-(3-chlorophenyl)-indol-1-yl]-acetic acid tert-butyl ester 

Relevant articles and documents

Total synthesis of (±) aspidostomide B, C, regioisomeric N-methyl aspidostomide D and their derivatives

A full account of the total synthesis of aspidostomide B, C, their analogues and our synthetic efforts towards the synthesis of aspidostomide D, which led to the synthesis of regioisomeric N-methyl aspidostomide D, its analogues via epoxide opening strategy is presented. The synthesis of regioisomeric N-methyl aspidostomide D involves an efficient, five-step sequence, with 36.3% overall yield, starting from 3,4,5-tribromo-1H-pyrrole-2-carboxylic acid. The key features of this protocol are intramolecular cyclization, dehydration, oxidation, and a Lewis acid-mediated regioselective epoxide ring opening by C-3 position of 2,5-dibromo-1H-indole to furnish the title compounds.

Substituted 3-alkyl and 3-arylalkyl 1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)

The invention formula substituted 3-alkyl and 3-arylalkyl 1H indol-1yl acetic acid derivatives which are useful as inhibitors of plasminogen activator inhibitor (PAI-1) useful for treating fibrinolytic disorders, the compounds having the structure wherein

Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)

This invention provides compounds of the formula: wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, or the salt or ester forms thereof, as well as methods for using the compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.